Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

Abstract

Objective:

To investigate characteristics of multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients associated with drugs other than natalizumab since our experience in other disease-modifying drugs (DMD) is still limited.

Methods:

This is a descriptive observational study within the FAERS database, registered between July 2015 and June 2017.

Results:

The primary cohort for the analysis consisted of 100,921 MS patients (mean (standard deviation (sd)) age, 48.9 (12.8) years, 20.9% male). Among them 786 (0.78%) developed PML. The adjusted odds ratio of PML for each drug was as follows; natalizumab 115.72 (95% CI; 83.83, 159.74), fingolimod 4.98 (3.64, 6.81) followed by dimethyl fumarate 1.77 (1.2, 2.62) and rituximab 3.22 (1.07, 9.72). The median time from the start of suspected drugs to the onset of PML for natalizumab and other agents were 1463 and 178 days, respectively. The proportion of PML appeared higher in Japan (2.4%) compared to that in the United States (0.24%).

Conclusion:

The reporting proportion of PML was relatively higher in natalizumab followed by fingolimod, dimethyl fumarate and rituximab. Other characteristics of PML associated with DMDs, including the time to onset and differences in reporting among countries, are described.

Keywords

Progressive multifocal leukoencephalopathy multiple sclerosis natalizumab rituximab fingolimod demography time to onset

Get full access to this article

View all access options for this article.

References

Bozic

Subramanyam

Richman

et al . Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol 2014; 21: 299–304.

D‘Amico

Zanghì

Leone

et al . Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: A comprehensive review of current evidence and future needs. Drug Saf 2016; 39: 1163–1174.

Mitchell

Bacher

Bernhage

n J

et al . Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol 1995; 154: 3863–3870.

Goldman

Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20(Suppl. C): C40–C44.

Hayashi

Boyko

Leonetti

et al . Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med 2004; 140: 992–1000.

Smits

Dippel

Steyerberg

et al . Predicting intracranial traumatic findings on computed tomography in patients with minor head injury: The CHIP prediction rule. Ann Intern Med 2007; 146: 397–405.

Astrom

Mancall

Richardson

Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin‘s disease. Brain 1958; 81: 93–111.

Brooks

Walker

Progressive multifocal leukoencephalopathy. Neurol Clin 1984; 2: 299–313.

Bernick

Gregorios

Progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome. Arch Neurol 1984; 41: 780–782.

10.

Miller

Barrett

Britton

et al . Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982; 307: 1436–1438.

11.

Snider

Simpson

Nielsen

et al . Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients. Ann Neurol 1983; 14: 403–418.

12.

Zaheer

Berger

Treatment-related progressive multifocal leukoencephalopathy: Current understanding and future steps. Ther Adv Drug Saf 2012; 3(5): 227–239.

13.

Bloomgren

Richman

Hotermans

et al . Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

14.

Carson

Evens

Richey

et al . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834–4840.

15.

Koralnik

Letvin

JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001; 75: 3483–3487.

16.

von Andrian

Engelhardt

. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68–72.

17.

Krumbholz

Meinl

Kümpfel

et al . Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71(17): 1350–1354.

18.

Houff

Major

Katz

et al . Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318: 301–305.

19.

Multiple Sclerosis Group TJS and of N. Information from The Japanese Society of Neuroimmunology. The Japanese Society of Neuroimmunology, 2017. http://www.neuroimmunology.jp/ (accessed 9 November 2017).